SCHEMBL4991419

SCHEMBL4991419

CCOC(=O)CNC(=O)c1c(O)nc(-c2ccc(OC)cc2)n(Cc2ccccc2)c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 1/20 0.49
ALDH1A1 P00352 7/20 0.48
HPGD P15428 5/20 0.48
GAA P10253 4/20 0.48
KDM4E B2RXH2 4/20 0.48
HTT P42858 3/20 0.48
MAPT P10636 3/20 0.48
NPSR1 Q6W5P4 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
TP53 P04637 1/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
RECQL P46063 1/20 0.46
RAB9A P51151 1/20 0.45
THRB P10828 1/20 0.44
MAPK1 P28482 2/20 0.44
EGLN1 Q9GZT9 2/20 0.43
EDNRB P24530 1/20 0.43
USP2 O75604 1/20 0.43
GLA P06280 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4992207 0.93 EGLN3 (0.54) EGLN3ALDH1A1HPGDKDM4ENPSR1
SCHEMBL4996231 0.91 EGLN3 (0.57) EGLN3ALDH1A1HPGDGAAKDM4E
SCHEMBL4995930 0.85 EGLN3 (0.65) EGLN3ALDH1A1HPGDTP53EGLN1
SCHEMBL4736985 0.84 EGLN3 (0.50) EGLN3ALDH1A1HPGDKDM4EHTT
SCHEMBL4992677 0.81 EGLN3 (0.48) EGLN3ALDH1A1HPGDKDM4ENPSR1
SCHEMBL4992247 0.80 EGLN3 (0.62) EGLN3ALDH1A1SMN1; SMN2RECQLRAB9A
SCHEMBL4737644 0.78 EGLN3 (0.47) EGLN3ALDH1A1HPGDGAAKDM4E
SCHEMBL3420468 0.76 HPGD (0.49) EGLN3ALDH1A1HPGDGAAKDM4E
SCHEMBL4988688 0.76 EGLN3 (0.78) EGLN3EGLN1
SCHEMBL4985650 0.76 EGLN3 (0.57) EGLN3KMT2AEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 EGLN3 3/4885ALDH1A1 513/4885HPGD 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.